Backers of ADCs have more good news coming from Europe today as the EU approves Adcetris for use in the treatment of relapsesed Hodgkin's and ALCL. Millennium (Takeda) licensed rights to sell the product outside the US from its inventor Seattle Genetics and will now pay the latter a $25 M milestone. SeaGen will also receive tiered double digit royalties on the sales of the product.
Thus ADCs continue their role as one of the hottest new technologies in the treatment of cancers. SeaGen has already generated nearly $150 M in sales in the US since the drug's approval earlier this year. Many companies now have ADC programs in their pipelines and there are 10's of drugs in clinical trials. This is only expected to expand with Adcetris' success so far and the expected approval soon of Roche's T-DM1 for breast cancer. See Xconomy.